Health Care • Biotechnology: Pharmaceutical Preparations
$927.89 ▲ +109.12
(+13.33%)
MKT CAP: $84.30B • VOL: 2.87M
52W L $592 52W H $935
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$779
MEDIAN
$1,039
MEAN
$1,058
HIGH
$1,262
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE REGN TAPE
REGN // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $1,122.75 | $1,067.07 | 2025-02-14 | $844.38 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $1,169.14 | $1,094.91 | 2025-02-06 | $872.22 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $1,057.79 | $1,020.68 | 2025-01-29 | $890.77 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $946.45 | — | 2025-01-17 | $909.33 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $816.54 | $881.50 | 2025-01-09 | $825.82 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $1,104.19 | $965.01 | 2024-12-18 | $807.26 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $900.05 | $937.17 | 2024-12-04 | $862.94 | -4.3% | 48% | C |